Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head & Neck Carcinoma, Phase III Randomized Clinical Trial

NCT00603759 is registered in ClinicalTrials.gov with Tehran University of Medical Sciences as lead sponsor.

NCT NCT00603759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00603759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head & Neck Carcinoma, Phase III Randomized Clinical Trial
Lead sponsor
Tehran University of Medical Sciences
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2006
Completion date
August 31, 2009
Enrollment
122 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer